{
  "id": 19131143,
  "title": "Vale Biolabs receives €164K from Venture Kick to advance brain disease research",
  "url": "https://urgent.news/2026/11/09/vale-biolabs-receives-164k-from-venture-kick-to-advance-brain-disease",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-09T09:30:00.000Z",
  "source": {
    "name": "Tech.eu",
    "slug": "tech-eu",
    "url": "https://tech.eu/2026/11/09/vale-biolabs-receives-eur164k-from-venture-kick-to-advance-brain-disease-research/"
  },
  "original_language": "en",
  "account": "Biotechnology company Vale Biolabs has secured €164,000 (CHF 150,000) from Venture Kick to further develop its innovative platform for investigating brain diseases and assessing potential remedies. The startup, established by Ilaria Incaviglia, Angeliki Damilou, Daniel Medina Cano, and Theodoulos Rodosthenous, integrates lab-grown human brain tissue, automation, and predictive artificial intelligence to assist researchers in comprehending how the brain reacts to medications and facilitate the creation of novel therapies. The founding team boasts expertise in organoid neurobiology, automation, data science engineering, and early-stage venture development, addressing the difficulties in developing treatments for neurological disorders due to the heavy reliance on animal testing in preclinical research. The dissimilarities between animal and human biology often hinder accurate predictions of drug efficacy in patients, leading to clinical trial failures, escalating development costs, and delayed new therapies. Vale Biolabs aims to tackle these issues by creating standardized human brain organoids—miniature tissue models that mirror specific aspects of the human brain. Through automation, the company observes alterations within these models over time, scrutinizing their structure, activity, and molecular reactions before and after exposure to potential treatments. The gathered data is utilized to formulate predictive AI models that bolster research into brain development, neurodegenerative diseases, and healthy brain aging. By enabling drug developers to evaluate treatments on human brain tissue earlier in the development process, the platform strives to identify promising therapies and potential failures prior to clinical trials. The technology has the potential to support research on various neurological conditions, including rare brain disorders and neurodegenerative diseases like Alzheimer's and Parkinson's, while potentially reducing development costs and expediting the introduction of new treatments. The funding from Venture Kick will aid Vale Biolabs in further refining its automated platform, enlarging its human brain organoid models, and generating datasets to train and verify its predictive AI models. Additionally, the financial support will facilitate collaborations with research and industry partners.",
  "summary": "Biotech startup Vale Biolabs has received€164,000 (CHF 150,000) from Venture Kick to advance its platform for studyingbrain diseases and evaluating potential treatments.Founded by Ilaria Incaviglia, A...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}